

REMARKS

The above preliminary amendment is made to cancel claims 1, 2, 7, 8, 16-25 and 27.

Editorial changes have been made to claims 5, 9, 13-15 and 26; claims 3, 10, 11, and 12 have been amended to depend from claim 5; and claim 28 now only depends from claim 26. New dependent claims 29-33 have been added. No new matter is added.

A new abstract page is supplied to conform to that appearing on the publication page of the WIPO application, but the new Abstract is typed on a separate page as required by U.S. practice.

A courtesy copy of the present specification is enclosed herewith. However, the World Intellectual Property Office (WIPO) copy should be relied upon if it is already in the U.S. Patent Office.


Applicants respectfully request that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.

If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicants' primary attorney-of record, Douglas P. Mueller (Reg. No. 30,300), at (612) 371.5237.

Respectfully submitted,



MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

By 
Douglas P. Mueller
Reg. No. 30,300

Dated: February 28, 2005

DPM/pjk

ABSTRACT

Kallikrein 5 constitutes a novel biomarker for diagnosis, treatment and monitoring of breast and ovarian cancer. A method is provided for diagnosing and monitoring breast or ovarian cancer or a predisposition to breast or ovarian cancer, in a subject comprising detecting kallikrein 5 in a sample from the subject. Imaging methods, screening methods for test agents for inhibiting breast or ovarian cancer, and therapeutic applications based on kallikrein 5 are also described.